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Background: The effectiveness of drug-eluting stents in patients with in-stent restenosis (ISR) after prior bare-metal stent implantation has been 
reported. The aim of this IVUS study was to compare the vessel response between sirolimus- (SES) and paclitaxel-eluting stents (PES) in patients 
with ISR.
Methods: Serial 3D IVUS analyses (baseline and 6-9 months) were performed in 92 patients with bare-metal ISR who were treated with SES 
(n=45) or PES (n=47). In addition to standard IVUS parameters, % length with cross-sectional narrowing (CSN) >50% (IH50) was computed to 
assess the diffuseness of severe lumen encroachment at follow-up.
Results: During follow-up, an increase in vessel and peri-stent plaque volume was observed in PES, but not in SES. At follow-up, neointimal 
obstruction and max. CSN were significantly lower in SES compared to PES (neointimal obstruction: 5.7% vs. 13.1%; max. CSN: 24.0% vs. 37.4%). 
Accordingly, follow-up lumen volume and minimum lumen area were both comparable between the 2 stents, despite a smaller stent VI at baseline 
observed in SES. SES showed a trend toward fewer IVUS-defined recurrent ISR (max. CSN >50%) compared with PES (13.3% vs. 29.8%, p=0.06). 
Among these cases, IH50 was similar (11.8% vs. 11.2%,p=0.93) between the 2 stents.
Conclusion: Treatment of bare-metal ISR with SES appears to reduce recurrent neointimal hyperplasia compared with PES. However, the pattern of 
recurrent ISR was similar, demonstrating relatively focal neointimal accumulation in both stents. 
